Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Vladimir Maletic, Gregory W. Mattingly & Jami Earnest. (2024) Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents. Expert Review of Neurotherapeutics 24:5, pages 443-455.
Read now
Read now
Rebecca Law, David Lewis, Daniel Hain, Rachel Daut, Melissa P. DelBello, Jean A. Frazier, Jeffrey H. Newcorn, Erika Nurmi, Elizabeth S. Cogan, Susanne Wagner, Holly Johnson & Jerry Lanchbury. (2022) Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using in vitro models of hepatic metabolism. Xenobiotica 52:7, pages 676-686.
Read now
Read now
Ann Childress & Shelby Burton. (2022) Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit/hyperactivity disorder. Expert Opinion on Drug Metabolism & Toxicology 18:6, pages 357-366.
Read now
Read now
Saraswathisreeram Pranush Kumar, Deeki Doma Sherpa, Amit Kumar Sahu, Tarang Jadav, Rakesh Kumar Tekade & Pinaki Sengupta. (2021) Innovation in Bioanalytical Strategies and in vitro Drug–drug Interaction Study Approaches in Drug Discovery. Bioanalysis 13:6, pages 513-532.
Read now
Read now
Mario Öeren, Peter A. Hunt, Charlotte E. Wharrick, Hamed Tabatabaei Ghomi & Matthew D. Segall. Predicting routes of phase I and II metabolism based on quantum mechanics and machine learning. Xenobiotica 0:0, pages 1-49.
Read now
Read now
Articles from other publishers (12)
Zhao Wang, Tesfaye Liranso, Zulane Maldonado-Cruz, Alisa R. Kosheleff & Azmi Nasser. (2024) Impact of Viloxazine Extended-Release Capsules (Qelbree®) on Select Cytochrome P450 Enzyme Activity and Evaluation of CYP2D6 Genetic Polymorphisms on Viloxazine Pharmacokinetics. Clinical Drug Investigation.
Crossref
Crossref
Richard Bade, Julia Huchthausen, Carolin Huber, Pradeep Dewapriya, Benjamin J. Tscharke, Rory Verhagen, Cheneal Puljevic, Beate I. Escher & Jake W. O'Brien. (2024) Improving wastewater-based epidemiology for new psychoactive substance surveillance by combining a high-throughput in vitro metabolism assay and LC−HRMS metabolite identification. Water Research 253, pages 121297.
Crossref
Crossref
N. A. Shnayder, A. V. Kidyaeva, E. E. Vaiman, A. R. Asadullin, M. M. Petrova, D. S. Kaskaeva, G. V. Matyushin, A. A. Evsyukov, E. V. Galko, N. P. Garganeeva, G. A. Chumakova, N. V. Lareva, N. G. Neznanov & R. F. Nasyrova. (2023) Role of Pharmacokinetics and Pharmacogenetics of Antidepressant-Induced Prolongation of the QT Interval and Torsade de Pointes in Patients with Mental Disorders. Personalized Psychiatry and Neurology 3:2, pages 72-119.
Crossref
Crossref
Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt & V. Sashi Gopaul. (2023) Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans. Drug Metabolism and Disposition 51:4, pages 464-479.
Crossref
Crossref
Christopher L Robinson, Katelyn Parker, Saurabh Kataria, Evan Downs, Rajesh Supra, Alan D. Kaye, Omar Viswanath & Ivan Urits. (2022) Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder. Health Psychology Research 10:3.
Crossref
Crossref
Hannah W Haddad, Paul B. Hankey, Jimin Ko, Zahaan Eswani, Pravjit Bhatti, Amber N. Edinoff, Adam M. Kaye & Alan D. Kaye. (2022) Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update. Health Psychology Research 10:2.
Crossref
Crossref
Zhao Wang, Alisa R Kosheleff, Lilian W Adeojo, Oyinkansola Odebo, Tesfaye Liranso, Stefan Schwabe & Azmi Nasser. (2021) Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (QelbreeTM) in Healthy Adult Subjects. European Journal of Drug Metabolism and Pharmacokinetics 47:1, pages 69-79.
Crossref
Crossref
Azmi Nasser, Roberto Gomeni, Zhao Wang, Alisa R. Kosheleff, Lanyi Xie, Lilian W. Adeojo & Stefan Schwabe. (2021) Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder. The Journal of Clinical Pharmacology 61:12, pages 1626-1637.
Crossref
Crossref
Zhao Wang, Alisa R. Kosheleff, Lilian W. Adeojo, Oyinkansola Odebo, Toyin Adewole, Peibing Qin, Vladimir Maletic, Stefan Schwabe & Azmi Nasser. (2021) Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults. Clinical Pharmacology in Drug Development 10:11, pages 1365-1374.
Crossref
Crossref
Yvette N. Lamb. (2021) Viloxazine: Pediatric First Approval. Pediatric Drugs 23:4, pages 403-409.
Crossref
Crossref
Shamia L. Faison, Nicholas Fry, Toyin Adewole, Oyinkansola Odebo, Zhao Wang, Vladimir MaleticAzmi Nasser. (2021) Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults. Journal of Clinical Psychopharmacology 41:2, pages 155-162.
Crossref
Crossref
Shamia L. Faison, Nicholas Fry, Toyin Adewole, Oyinkansola Odebo, Stefan Schwabe, Zhao Wang, Vladimir Maletic & Azmi Nasser. (2020) Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults. Clinical Drug Investigation 41:2, pages 149-159.
Crossref
Crossref